Gilead and Arcus Announce Promising Results of Domvanalimab Plus Zimberelimab and Chemotherapy in Upper GI Cancers
FOSTER CITY, Calif. & HAYWARD, Calif. - Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have released updated data from the Phase 2 EDGE-Gastric study, showcasing the extended efficacy and safety results of their combination drug therapy. The study focuses on patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (upper GI cancers). In addition, Gilead Sciences has shared an update on the Phase 3 TROPiCS-04 study, evaluating Trodelvy (sacituzumab govitecan-hziy; SG) in patients with locally advanced or metastatic urothelial cancer (mUC).
The results from Arm A1 of the EDGE-Gastric study demonstrated a consistent response rate (ORR) and provided mature progression-free survival (PFS) data in patients with upper GI cancers. Domvanalimab, Zimberelimab, and chemotherapy in combination exhibited an impressive median PFS of over one year, making it a promising first-line treatment option for patients with these cancers. The extended follow-up supports the potential of this combination therapy to provide long-lasting benefits.
Upper GI cancers, including gastric, gastroesophageal junction, and esophageal adenocarcinoma, pose significant challenges and can be difficult to treat, especially when diagnosed at an advanced stage. Therefore, the longer-term efficacy results from the EDGE-Gastric study are encouraging, as they offer hope for improved treatment outcomes and extended survival for patients in this population.
Additionally, Gilead Sciences’ TROPiCS-04 study evaluated the efficacy of Trodelvy, a previously approved drug, in patients with locally advanced or metastatic urothelial cancer who had received platinum-containing chemotherapy and anti-PD-(L)1 therapy. Unfortunately, the study did not meet its primary endpoint. While this is disappointing news, it highlights the importance of ongoing research and the need for continued efforts to develop effective treatments for urothelial cancer.
The findings from both studies emphasize the complexities of cancer treatment and the need for personalized therapies tailored to specific cancer types. The results of the EDGE-Gastric study offer optimism for patients with upper GI cancers, indicating that the combination of domvanalimab, zimberelimab, and chemotherapy could significantly extend progression-free survival. It is important to note that these results are still based on clinical trials and further research is required to validate the findings.
The combination therapy of domvanalimab, zimberelimab, and chemotherapy represents a potential breakthrough in the treatment of upper GI cancers. The data suggest that this combination could become a first-line treatment option, providing hope to patients facing previously limited treatment choices. The research and development efforts led by Gilead Sciences and Arcus Biosciences highlight their commitment to improving patient outcomes and revolutionizing cancer treatment.
In conclusion, the updated results from the EDGE-Gastric study and the announcement of the TROPiCS-04 study outcomes reflect the ongoing efforts to advance cancer treatment options. While there are both successes and setbacks in the field of oncology, the promising findings of the EDGE-Gastric study offer hope to patients with upper GI cancers, while the TROPiCS-04 study reminds us of the challenges that remain in finding effective treatments for urothelial cancer.
Comments